Overview

• Zentalis Q2 operating expenses decreased to $36.1 mln from $65.1 mln last year

• Company maintains $303.4 mln cash position, supporting operations into late 2027

• DENALI Phase 2 trial on track, topline data expected by year-end 2026

Outlook

• Company expects topline data from DENALI trial by end of 2026

• Zentalis has cash runway into late 2027

• DENALI trial could support accelerated approval, pending FDA feedback

• Company focused on late-stage development of azenosertib

Result Drivers

• STRATEGIC RESTRUCTURING - Completed restructuring prioritizes late-stage development of azenosertib, reducing operating expenses and extending cash runway into late 2027

• CLINICAL DEVELOPMENT - Continued focus on advancing azenosertib in Cyclin E1-positive PROC patients, with DENALI Phase 2 trial on track for topline data by year-end 2026

• EXPENSE REDUCTION - Significant decrease in R&D expenses due to reduced clinical, lab, and drug manufacturing costs

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00, about 76.5% above its August 5 closing price of $1.41

Press Release: ID:nGNX24nzsn

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)